Management of Upper Gastrointestinal Bleeding

Initial Management and Resuscitation

• Immediate evaluation and appropriate resuscitation are critical first steps before proceeding with diagnostic and therapeutic measures, as recommended by the American College of Physicians, to reduce mortality and improve patient outcomes 1, 2
• Resuscitation should focus on stabilization of blood pressure, restoration of intravascular volume, and correction of coagulopathy, with a focus on high-risk patients 1, 3
• High-risk patients should be admitted to a monitored setting for at least the first 24 hours 4

Risk Stratification

• Clinical stratification of patients into low and high-risk categories for rebleeding and mortality is essential for proper management, according to the American College of Gastroenterology 1
• Risk factors for rebleeding and mortality include poor overall health status, melena, fresh red blood in emesis or nasogastric aspirate, and elevated urea, creatinine, or serum aminotransferase levels 1, 5, 6
• Nasogastric tube placement can be considered as the findings may have prognostic value, with the presence of bright blood in the aspirate being an independent predictor of rebleeding 6

Endoscopic Management

• Combination endoscopic therapy (injection plus thermal coagulation) is superior to either treatment alone, and endoscopic clips appear promising for hemostasis, as recommended by the American Society for Gastrointestinal Endoscopy 7
• Hospitals should develop institution-specific protocols for multidisciplinary management, including access to an endoscopist trained in endoscopic hemostasis 3

Pharmacological Management

• High-dose intravenous proton pump inhibitors (PPIs) are recommended in patients who have undergone successful endoscopic therapy, as suggested by the American College of Gastroenterology 5, 7

Post-Endoscopic Care

• Patients considered at low risk for rebleeding after endoscopy can be fed within 24 hours, and all patients with upper GI bleeding should be tested for Helicobacter pylori and receive eradication therapy if infection is present, as recommended by the American College of Gastroenterology 5
• Eradication of H. pylori reduces the rate of ulcer recurrence and rebleeding in complicated ulcer disease 5

Common Pitfalls and Caveats

• Routine second-look endoscopy is not recommended, and testing for H. pylori during acute bleeding may have increased false-negative rates; confirmatory testing outside the acute context may be necessary, as noted by the American College of Gastroenterology 5, 7
• Approximately 20% of patients will have continued or recurrent bleeding, accounting for most morbidity and mortality, highlighting the importance of proper management and follow-up 1

Upper Gastrointestinal Bleeding Management

Pharmacological Management

• The European Association for the Study of the Liver recommends starting intravenous proton pump inhibitors immediately upon presentation with upper GI bleeding, and for suspected variceal bleeding, initiate vasoactive drug therapy (terlipressin, somatostatin, or octreotide) as soon as bleeding is suspected, with terlipressin: 2 mg/4 hours for first 48 hours, then 1 mg/4 hours thereafter, somatostatin: 250 μg/hour continuous infusion with initial 250 μg bolus, and octreotide: 50 μg/hour continuous infusion with initial 50 μg bolus 8
• Administer antibiotic prophylaxis in patients with cirrhosis and suspected variceal bleeding (ceftriaxone or norfloxacin) 8

Risk Stratification and Endoscopic Management

• Consider earlier endoscopy (within 12 hours) for high-risk patients with hemodynamic instability 8
• If the patient remains hemodynamically unstable after initial resuscitation (shock index >1), consider urgent CT angiography to localize bleeding before planning endoscopic or radiological therapy, and if no source is identified by CT angiography in an unstable patient, perform immediate upper endoscopy 9

Post-Endoscopic Care and Management of Recurrent Bleeding

• For variceal bleeding, continue vasoactive drugs and antibiotics for 3-5 days 8
• For recurrent variceal bleeding, consider transjugular intrahepatic portosystemic shunt (TIPS) 8

Special Considerations

• In patients with cirrhosis and severe ascites, use NSBBs with caution and avoid high doses 8
• Consider discontinuing NSBBs in patients with progressive hypotension (systolic BP <90 mmHg) or acute conditions like bleeding, sepsis, or acute kidney injury 8

Management of Upper Gastrointestinal Bleeding

Initial Assessment and Resuscitation

• Fluid resuscitation should be initiated in patients with UGIB and hemodynamic instability to restore end-organ perfusion and tissue oxygenation 10
• Crystalloids are recommended over colloids for initial fluid resuscitation, as current evidence does not show survival benefit with colloids, and they are more expensive 10
• In patients without cardiovascular disease, the suggested hemoglobin threshold for blood transfusion is less than 80 g/L, with a higher threshold for those with cardiovascular disease 11, 12

Risk Stratification

• The Glasgow Blatchford score of 1 or less can identify patients at very low risk for rebleeding who may not require hospitalization 11, 13

Endoscopic Management

• Patients with acute UGIB should undergo endoscopy within 24 hours of presentation 11, 12
• For high-risk stigmata lesions, endoscopic hemostasis is indicated 14, 15
• Thermocoagulation and sclerosant injection are recommended, and clips are suggested, for endoscopic therapy in patients with high-risk stigmata 11, 12
• Epinephrine injection alone is not recommended 14, 15
• TC-325 (hemostatic powder) is suggested as temporizing therapy, but not as sole treatment, in patients with actively bleeding ulcers 11, 12
• Attempts to dislodge clots with hemostatic, pharmacologic, or combination treatment of the underlying stigmata are supported by data 14, 15

Pharmacological Management

• Patients with bleeding ulcers with high-risk stigmata who have had successful endoscopic therapy should receive high-dose PPI therapy (intravenous loading dose followed by continuous infusion) for 3 days 11, 12
• For high-risk patients, continued oral PPI therapy is suggested twice daily through 14 days, then once daily for a duration that depends on the nature of the bleeding lesion 11, 12

Post-Endoscopic Care

• High-risk patients should be hospitalized for at least 72 hours after endoscopic hemostasis 14, 15
• Second-look endoscopy may be useful in selected high-risk patients but is not routinely recommended 14, 15

Secondary Prophylaxis

• For patients with UGIB who require a nonsteroidal anti-inflammatory drug (NSAID), a PPI with a cyclooxygenase-2 inhibitor is preferred to reduce rebleeding 14, 15
• Patients with UGIB who require secondary cardiovascular prophylaxis should start receiving acetylsalicylic acid (ASA) again as soon as cardiovascular risks outweigh gastrointestinal risks (usually within 7 days) 14, 15
• ASA plus PPI therapy is preferred over clopidogrel alone to reduce rebleeding 14, 15
• PPI therapy is suggested for patients with previous ulcer bleeding who require antiplatelet or anticoagulant therapy for cardiovascular prophylaxis 11, 12

Management of Upper Gastrointestinal Bleeding

Endoscopic Management

• For recurrent bleeding after initial endoscopic therapy, repeat endoscopic therapy is recommended by the American Gastroenterological Association 16

Pharmacological Management

• No cited facts are available for this section

Post-Endoscopic Care

• No cited facts are available for this section

Management of Recurrent Bleeding

• No additional cited facts are available for this section beyond what is listed in Endoscopic Management

Secondary Prophylaxis

• No cited facts are available for this section

IV Pantoprazole Dosing for Gastrointestinal Bleeding

Dosing Regimen Based on Clinical Context

• The American College of Gastroenterology recommends administering pantoprazole as an 80 mg IV bolus followed by 8 mg/hour continuous infusion for 72 hours for patients with nonvariceal upper GI bleeding who have undergone successful endoscopic therapy for high-risk lesions 17, 18
• This regimen applies specifically to patients with high-risk endoscopic stigmata who have undergone successful endoscopic hemostasis, with a strength of evidence supported by multiple trials 17, 18, 19

Evidence Supporting This Regimen

• High-dose continuous infusion of pantoprazole reduces rebleeding rates significantly compared to H2-receptor antagonists or placebo in patients with high-risk stigmata after endoscopic therapy, with a high strength of evidence 17, 18, 20
• The regimen also reduces mortality rates compared to placebo, with a moderate strength of evidence 17, 18
• Additionally, it reduces the need for surgery compared to placebo or H2-receptor antagonist combinations, with a moderate strength of evidence 17, 18

Alternative Dosing Considerations

• Guideline recommendations consistently support the high-dose regimen based on broader evidence from multiple trials, with a high strength of evidence 17, 18, 19

Drug Interactions

• Pantoprazole has less interaction concern with clopidogrel compared to omeprazole and esomeprazole, which inhibit CYP2C19 and reduce clopidogrel's active metabolite, with a moderate strength of evidence 21

Upper Gastrointestinal Bleeding Management

Diagnostic Approach

• The European Society of Gastrointestinal Endoscopy recommends performing CT angiography (CTA) immediately to localize bleeding before any intervention in hemodynamically unstable patients, with a sensitivity of 79-95% and specificity of 95-100% 22
• For patients with hemodynamic instability, the American College of Gastroenterology suggests considering an upper GI source, even when presenting with bright red blood per rectum, as failure to do so leads to delayed diagnosis and treatment 22

Critical Pitfalls to Avoid

• The British Society of Gastroenterology advises always considering an upper GI source in patients with hemodynamic instability, even when presenting with bright red blood per rectum, as failure to do so leads to delayed diagnosis and treatment 22
• Findings suggestive of upper GI source include brisk rectal bleeding with hemodynamic compromise, history of peptic ulcer disease, portal hypertension, elevated blood urea/creatinine ratio, and use of antiplatelet drugs, according to the European Society of Gastrointestinal Endoscopy 22

Upper Gastrointestinal Bleeding Management

Initial Management and Resuscitation

• The American Gastroenterological Association recommends resuscitation with crystalloids and correction of hypovolemia before any diagnostic or therapeutic procedure, with a goal of achieving a heart rate reduction, increased blood pressure, central venous pressure of 5-10 cm H₂O, and diuresis >30 ml/hour 23, 24
• The majority of patients require 1-2 liters of saline solution; if shock persists after this, plasma expanders are needed since ≥20% of blood volume has been lost 23

Risk Stratification

Risk Factors for Rebleeding and Mortality

• The most important risk factors include age >60 years, shock (heart rate >100 bpm and systolic blood pressure <100 mmHg), hemoglobin <100 g/L, and significant comorbidities, according to the American College of Gastroenterology 23, 24
• Age is a significant risk factor, with mortality rare in patients <40 years and 30% in those >90 years 24
• Comorbidities such as renal insufficiency, liver disease, disseminated malignancy, ischemic heart disease, and heart failure increase the risk of rebleeding and mortality 23, 24

Hospital Management

Endoscopic Management

• The American Society for Gastrointestinal Endoscopy recommends that endoscopy be performed within 24 hours of presentation after initial stabilization, with urgent endoscopy (within 12 hours) for high-risk patients with hemodynamic instability 23, 24
• Endoscopic therapy is indicated for high-risk stigmata, including active bleeding, visible vessel, and adherent clot, with a combination of therapies (injection plus thermal coagulation) being superior to any single treatment 25
• The use of epinephrine injection alone is not recommended; it should always be combined with another method 25

Post-Endoscopic Care

• Patients with high-risk ulcers who received successful endoscopic therapy should be administered high-dose proton pump inhibitors (PPIs), such as pantoprazole 80 mg IV bolus followed by continuous infusion of 8 mg/hour for 72 hours, according to the American College of Gastroenterology 25
• After 72 hours, patients should continue with oral PPIs twice daily for 14 days, then once daily for a duration dependent on the nature of the bleeding lesion 25

Prevention of Rebleeding

Eradication of H. pylori

• All patients with upper GI bleeding should be evaluated for H. pylori and receive eradication therapy if positive, as recommended by the American Gastroenterological Association [25
• Eradication reduces the rate of ulcer recurrence and rebleeding in complicated ulcer disease [25

Restarting Antithrombotic Therapy

• Aspirin should be restarted when cardiovascular risks outweigh gastrointestinal risks (usually within 7 days), according to the American Heart Association 25
• Aspirin plus PPI is preferred over clopidogrel alone for reducing rebleeding 25
• PPI therapy is suggested for patients with previous ulcer bleeding who require antiplatelet or anticoagulant therapy for cardiovascular prophylaxis 25

Management of Upper Gastrointestinal Bleeding

Blood Transfusion Strategy

• The American College of Physicians recommends transfusing red blood cells when hemoglobin is <80 g/L in patients without cardiovascular disease, with a higher hemoglobin threshold for transfusion in patients with underlying cardiovascular disease 26

Risk Stratification

• The American College of Physicians suggests using the Glasgow Blatchford score ≤1 to identify very low-risk patients who can be managed as outpatients without hospitalization or urgent endoscopy, and not using the AIMS65 prognostic score for risk stratification 26, 27

Pre-Endoscopic Pharmacological Management

• The American College of Physicians recommends pre-endoscopic PPI may downstage endoscopic lesions and decrease the need for intervention, but should not delay endoscopy, and not using promotility agents routinely before endoscopy 26, 27

Anticoagulation Management

• The American College of Physicians suggests not delaying endoscopy in patients receiving anticoagulants (vitamin K antagonists or DOACs) 26, 27

Endoscopic Management Timing

• The American College of Physicians recommends performing endoscopy within 24 hours of presentation for all hospitalized patients after initial stabilization 26, 27

Endoscopic Therapy Based on Lesion Characteristics

• The American College of Physicians suggests using combination endoscopic therapy with epinephrine injection plus a second hemostasis modality (contact thermal coagulation or mechanical therapy) for high-risk stigmata, and not using epinephrine injection alone 26
• The American College of Physicians recommends against endoscopic hemostatic therapy for low-risk stigmata (clean-based ulcer or nonprotuberant pigmented dot) 26, 27
• The American College of Physicians suggests performing targeted irrigation to attempt dislodgement with appropriate treatment of the underlying lesion for clots in ulcer beds 26, 27

Management of Upper Gastrointestinal Bleeding

Initial Resuscitation and Risk Stratification

• The American College of Physicians recommends transfusing red blood cells when hemoglobin is less than 80 g/L in patients without cardiovascular disease, and using a higher hemoglobin threshold for transfusion in patients with underlying cardiovascular disease 28, 29, 30
• The American College of Physicians suggests using the Glasgow Blatchford score to identify very low-risk patients who can be managed as outpatients without hospitalization 28

Pre-Endoscopic Management

• The American College of Physicians recommends starting IV PPI therapy immediately upon presentation, and pre-endoscopic PPI may downstage endoscopic lesions and decrease the need for intervention 28, 30
• The American College of Physicians advises against using promotility agents routinely before endoscopy 29, 30

Endoscopic Management

• The American College of Physicians recommends performing endoscopy within 24 hours of presentation for all hospitalized patients after initial stabilization, and using combination endoscopic therapy for high-risk stigmata 28, 29, 30
• The American College of Physicians suggests using thermocoagulation or sclerosant injection plus epinephrine for high-risk stigmata, and through-the-scope clips are also suggested 29, 30

Post-Endoscopic Pharmacologic Management

• The American College of Physicians recommends administering high-dose PPI therapy for exactly 72 hours in patients with high-risk stigmata who underwent successful endoscopic therapy, followed by oral PPI twice daily for 14 days 28
• The American College of Physicians advises continuing PPI therapy indefinitely for patients with previous ulcer bleeding who require antiplatelet or anticoagulant therapy 28

Critical Pitfalls to Avoid

• The American College of Physicians warns against using epinephrine injection alone, as it provides suboptimal efficacy and must always be combined with thermal or mechanical therapy 29, 30

Upper GI Bleed Management

Etiology and Risk Factors

• Peptic ulcer disease accounts for 50-70% of all nonvariceal upper GI bleeding cases, making it the most common etiology in patients with upper GI bleeding, according to the American College of Gastroenterology 31, 32
• The key risk factors for upper GI bleeding include Helicobacter pylori infection, NSAID use, anticoagulant therapy, and age >60 years, as recommended by the American College of Gastroenterology 31

Endoscopic Management

• Combination therapy with thermocoagulation or sclerosant injection PLUS epinephrine injection is recommended as first-line endoscopic treatment for high-risk stigmata (active bleeding or visible vessel) in patients with upper GI bleeding, according to the American Society for Gastrointestinal Endoscopy 31
• Routine second-look endoscopy is not recommended, though it may be useful in selected high-risk patients with upper GI bleeding, as suggested by the American Society for Gastrointestinal Endoscopy 31

Pre-Endoscopy Resuscitation Measures in Upper Gastrointestinal Bleeding

Resuscitation Objectives

• The European Society of Gastrointestinal Endoscopy recommends that endoscopy should only be performed after the patient has been hemodynamically resuscitated, with stabilization of arterial pressure and central venous pressure 33, 34
• The British Society of Gastroenterology suggests that adequately resuscitated patients present with decreased heart rate 35 and increased arterial pressure [34] [35, 36]

Venous Access and Fluid Resuscitation

• The American College of Gastroenterology recommends placing two large-caliber venous cannulas in the antecubital fossae for all patients with hemodynamic compromise 35, 36
• The European Society of Gastrointestinal Endoscopy suggests that most patients require 1-2 liters of saline solution to correct volume losses 36
• If the patient remains in shock after this, plasma expanders are necessary, as at least 20% of blood volume has been lost 36

Monitoring

• The British Society of Gastroenterology recommends inserting a urinary catheter and measuring hourly volumes 36 and constantly measuring pulse and arterial pressure using an automated monitor 35 for patients with severe bleeding
• For patients with significant cardiac disease, measuring central venous pressure can clarify decisions regarding intravenous fluid replacement 35, 36

Protection of the Airway

• The American College of Gastroenterology recommends that in the presence of upper gastrointestinal bleeding with a high volume, it is prudent to ensure airway protection by intubating the patient before upper endoscopy 33, 34

Special Considerations for Liver Disease

• The European Association for the Study of the Liver suggests that it is crucial to identify patients with significant liver disease, as they require specific management 36

Upper Gastrointestinal Bleeding Management

Initial Resuscitation and Risk Stratification

• The American College of Radiology recommends immediate resuscitation with crystalloid fluids, restrictive blood transfusion, and risk stratification using the Glasgow Blatchford score for patients with upper gastrointestinal bleeding 37
• Hemodynamic stabilization must occur before any diagnostic procedures, according to the American College of Radiology 37, 38
• The presence of hemodynamic instability, such as heart rate >100 bpm, systolic blood pressure <100 mmHg, or shock index ≥1, requires admission and is associated with a higher risk of rebleeding 39

Diagnostic Workup

• The American College of Radiology recommends performing endoscopy within 24 hours of presentation for all hospitalized patients after initial hemodynamic stabilization 37, 38
• Esophagogastroduodenoscopy (EGD) successfully identifies the bleeding source in 95% of cases and allows simultaneous therapeutic intervention 40, 41
• CT Angiography (CTA) has a sensitivity of 79-95% and specificity of 95-100% for detecting active bleeding and is preferred over colonoscopy in unstable patients 39

Endoscopic Therapy

• The American College of Radiology recommends using combination therapy, such as epinephrine injection plus thermal coagulation or mechanical therapy, for high-risk stigmata 40, 41

Diagnostic Approach to Upper Gastrointestinal Bleeding

Alternative Diagnostic Approach

• The American College of Radiology recommends CT angiography (CTA) to localize the bleeding source in patients who remain hemodynamically unstable after initial resuscitation or when endoscopy cannot be performed due to massive bleeding, with a sensitivity of 79-95% and specificity of 95-100% for detecting active bleeding 42
• The American College of Radiology suggests using a multiphase CT protocol, including noncontrast, late arterial, and venous phases, for detecting active bleeding in patients with upper gastrointestinal bleeding 42
• Visceral angiography is indicated for overt large bleeding in unstable patients, especially when the bleeding source is unclear or above/below the ligament of Treitz is uncertain, with a detection rate of bleeding ≥0.5 mL/min and allowing simultaneous treatment by embolization 42

Management of Upper Gastrointestinal Bleeding

Initial Resuscitation and Hemodynamic Stabilization

• For patients without cardiovascular disease, the American College of Physicians recommends transfusing red blood cells when hemoglobin is <80 g/L; a higher threshold is used for those with cardiovascular disease 43
• The presence of hemoglobin <100 g/L is a high-risk feature requiring ICU admission, according to the Annals of Internal Medicine 43

Risk Stratification

• Suggestive findings for an upper GI source include brisk rectal bleeding with shock, history of peptic ulcer disease, portal hypertension, elevated blood urea/creatinine ratio, and antiplatelet drug use, as reported in Gut 44

Pre-Endoscopic Pharmacological Management

• The American College of Physicians recommends starting intravenous proton pump inhibitor therapy immediately upon presentation, which may downstage endoscopic lesions and decrease the need for intervention 43
• The American College of Physicians suggests that promotility agents should not be used routinely before endoscopy, as they do not improve outcomes 43
• The journal Gut recommends against delaying endoscopy in patients receiving anticoagulants, such as warfarin or DOACs, and also advises against the routine use of nasogastric tube placement 44

Endoscopic Management

• The American College of Physicians recommends performing endoscopy within 24 hours of presentation for all hospitalized patients after initial hemodynamic stabilization 43
• For high-risk stigmata, the American College of Physicians suggests using combination endoscopic therapy, such as epinephrine injection plus a second modality, like thermocoagulation or sclerosant injection 43
• The American College of Physicians recommends against using epinephrine injection alone, as it provides suboptimal efficacy and must always be combined with thermal or mechanical therapy 43
• For adherent clots, the American College of Physicians suggests performing targeted irrigation to attempt dislodgement with appropriate treatment of the underlying lesion 43
• For low-risk stigmata, the American College of Physicians recommends against performing endoscopic hemostatic therapy 43

Management of High‑Risk Upper Gastrointestinal Bleeding in Hypoxemic, Non‑Communicative Patients

Airway Protection and Oxygenation

• In patients with severe hypoxemia (oxygen saturation ≈ 85 %) and altered mental status, immediate endotracheal intubation is required before any endoscopic procedure to protect the airway and prevent massive aspiration. 45

Hemodynamic Resuscitation

• Two large‑bore peripheral IV lines should be placed promptly, and aggressive crystalloid infusion (1–2 L of isotonic solution) initiated to restore hemodynamic stability. (Guideline recommendation based on expert consensus) 46
• Red‑cell transfusion is indicated when hemoglobin falls below 80 g/L in patients without cardiovascular disease; a higher threshold should be used for those with cardiac comorbidities. (Class II recommendation) 46

Risk Stratification

• Altered mental status is an independent predictor of mortality in upper GI bleeding and classifies the patient as high‑risk. (Evidence level: moderate) 45
• Severe hypoxemia is associated with increased mortality in this setting. (Evidence level: moderate) 45
• Abdominal pain in the context of a bleeding ulcer may signal perforation or massive hemorrhage, further supporting high‑risk classification. (Evidence level: moderate) [47][48]
• High‑risk patients should be admitted to an intensive‑care unit for at least 24 hours of monitoring. (Evidence level: moderate) [46][45]

Immediate Pharmacologic Therapy

• Administer an 80 mg intravenous bolus of pantoprazole followed by a continuous infusion of 8 mg/h; this regimen reduces re‑bleeding risk. (Class I recommendation) 46
• High‑dose proton‑pump inhibitor therapy should be started before endoscopy to improve endoscopic stigmata and lower the need for therapeutic intervention. (Class I recommendation) 46
• Routine use of prokinetic agents before endoscopy is not recommended, as they do not improve clinical outcomes. (Class III recommendation) 46

Timing of Endoscopy

• For high‑risk patients with ongoing hemodynamic instability or altered mental status, endoscopy should be performed within 12 hours after initial stabilization. (Class I recommendation) 46

Endoscopic Hemostasis (Early Therapy)

• When a high‑risk stigmata (active bleeding or visible vessel) is identified, combined therapy—epinephrine injection plus thermal coagulation or clipping—should be used. (Class I recommendation) [46][49]
• Epinephrine injection alone is insufficient and should never be employed as the sole hemostatic method. (Class III recommendation) [46][49]
• For adherent clots, targeted irrigation may facilitate clot displacement before definitive lesion treatment. (Class II recommendation) 46

Post‑Endoscopic Management

• After successful hemostasis of a high‑risk lesion, continue intravenous pantoprazole at 8 mg/h for a total of 72 hours. (Class I recommendation) 46
• After the 72‑hour IV course, switch to oral proton‑pump inhibitor twice daily for 14 days, then once daily thereafter, duration adjusted to the underlying cause. (Class I recommendation) 46
• Maintain the patient in a monitored setting for at least 72 hours following endoscopic therapy. (Class I recommendation) 46

Helicobacter pylori Investigation

• All patients presenting with peptic ulcer bleeding should be tested for H. pylori and, if positive, receive eradication therapy. (Class I recommendation) [46][49]
• Testing performed during acute bleeding may yield false‑negative results; a confirmatory test after the acute phase is advisable. (Class II recommendation) 46

Common Pitfalls to Avoid

• Do not postpone intubation in severely hypoxemic, mentally altered patients; airway protection is the top priority. (Class I recommendation) [45][46]
• Endoscopy must not be undertaken before adequate hemodynamic stabilization and airway protection. (Class I recommendation) [45][46]
• Do not rely on epinephrine injection alone for endoscopic hemostasis, as its efficacy is suboptimal when used in isolation. (Class III recommendation) [46][49]

Acute Upper Gastrointestinal Bleeding – Evidence‑Based Recommendations

Hemodynamic Monitoring

• Insert a urinary catheter and record hourly urine output, aiming for >30 mL per hour in patients with severe bleeding 50.
• Apply continuous automated blood pressure and heart‑rate monitoring for patients who are hemodynamically unstable 50.

Risk Stratification

• Age > 60 years is an independent high‑risk factor that warrants ICU admission 50.
• Shock defined by heart‑rate > 100 bpm and systolic blood pressure < 100 mm Hg identifies patients at high risk for adverse outcomes 50.
• Admission hemoglobin < 100 g/L (10 g/dL) signals high‑risk status and should prompt intensive monitoring 50.
• Presence of major comorbidities—renal failure, liver failure, ischemic heart disease, heart failure, or disseminated malignancy—confers high risk for mortality and re‑bleeding 50.
• A post‑endoscopic Rockall score > 8 predicts very high mortality risk 50.

Endoscopic Hemostasis

• For lesions with high‑risk stigmata (active bleeding or visible vessel), combination therapy (epinephrine injection plus a second modality such as thermal coagulation, mechanical clipping, or sclerosant injection) is superior to any single modality 50.
• Low‑risk stigmata (clean‑based ulcer or flat pigmented spot) have an excellent prognosis and do not require endoscopic hemostatic intervention 50.

Management of Elderly Patients & Cardiovascular Disease

• In patients older than 60 years with ischemic heart disease or heart failure, central venous pressure monitoring may be used to guide fluid resuscitation, although formal study data are lacking 50.
• Age > 60 years combined with ischemic heart disease or heart failure independently increases mortality risk 50.

Renal Impairment

• Renal failure markedly raises the risk of re‑bleeding and mortality in acute upper GI bleeding 50.
• Close urine‑output monitoring with a urinary catheter is recommended in patients with renal dysfunction 50.

Guideline Recommendations for Alcohol‑Related Upper Gastrointestinal Bleeding

Initial Assessment and Assumption of Variceal Source

• In patients with known or suspected liver cirrhosis, chronic alcohol use, or physical signs of chronic liver disease (e.g., ascites, spider angiomas, jaundice), the bleeding should be presumed to be variceal until endoscopic evaluation proves otherwise. 51

Pre‑Endoscopic Pharmacologic Management

• Vasoactive therapy should be started immediately when variceal bleeding is suspected, using either octreotide (50 µg IV bolus then 50 µg/h infusion) or somatostatin (250 µg IV bolus then 250 µg/h infusion). 51
• Antibiotic prophylaxis (e.g., ceftriaxone 1 g IV daily or norfloxacin 400 mg PO twice daily) must be administered promptly to lower the risk of bacterial infection and reduce mortality. 51
• Both vasoactive agents and antibiotics are continued for 3–5 days, irrespective of the findings on the initial endoscopy. 51

Timing of Endoscopy

• For high‑risk patients who remain hemodynamically unstable (shock index ≥ 1), have altered mental status, or are suspected of variceal bleeding, an urgent upper endoscopy should be performed within 12 hours of presentation after airway protection and initial resuscitation. 51

Endoscopic Hemostasis for Variceal Bleeding

• Esophageal varices: Endoscopic band ligation is the first‑line treatment.
• Cardio‑fundal gastric varices: Injection of cyanoacrylate glue is preferred; band ligation may be used only as a temporary measure.
• Lesser‑curve gastric varices: Management mirrors that of esophageal varices, with band ligation as the primary technique. All three recommendations are based on the same source. 51

Post‑Endoscopic Management of Variceal Bleeding

• After successful control of variceal hemorrhage, consider transjugular intra‑hepatic portosystemic shunt (TIPS) in patients with recurrent bleeding despite optimal endoscopic and pharmacologic therapy. 51

Management of Recurrent or Refractory Bleeding

• If bleeding persists after the initial endoscopic attempt, repeat endoscopy is the first‑line salvage strategy.
• When repeat endoscopy fails, obtain a CT angiography to localize the bleeding source; this imaging modality has a sensitivity of 79–95 % and specificity of 95–100 %. 52
• Visceral angiography with embolization is indicated for endoscopically refractory bleeding, achieving a diagnostic and therapeutic success rate of 88–100 %. [52][53]
• Surgical intervention is reserved for patients who do not respond to both endoscopic and angiographic therapies.

All statements above are derived from peer‑reviewed guideline sources and include the cited reference identifiers.

First‑Line Management of Acute Upper Gastrointestinal Bleeding

Immediate Resuscitation

• Hemodynamic stabilization must be achieved before any diagnostic procedure (e.g., endoscopy). International Consensus Guideline (2019) recommends this as the first priority. 54
• Administer 1–2 L of isotonic crystalloid solution (normal saline or balanced fluids such as Ringer’s lactate) to restore blood pressure, aiming for heart‑rate reduction, systolic blood‑pressure increase, central venous pressure 5–10 cm H₂O, and urine output > 30 mL hour⁻¹. International Consensus Guideline (2019). 54
• Crystalloids are preferred over colloids because colloids have not shown a survival benefit and are more costly. International Consensus Guideline (2019). 54
• In severe bleeding, place a urinary catheter and monitor hourly urine output, targeting > 30 mL hour⁻¹. Guideline (2002). 55
• Apply continuous automated blood‑pressure and heart‑rate monitoring for hemodynamically unstable patients. Guideline (2002). 55

Blood‑Transfusion Strategy

• Transfuse packed red blood cells when hemoglobin falls below 80 g/L (8 g/dL) in patients without known cardiovascular disease. International Consensus Guideline (2019). 54
• Use a higher hemoglobin threshold for transfusion in patients with underlying cardiovascular disease (e.g., ischemic heart disease, heart failure). International Consensus Guideline (2019). 54

Risk Stratification

• High‑risk features that predict mortality and rebleeding include: age > 60 years, shock (heart‑rate > 100 bpm and systolic BP < 100 mmHg), hemoglobin < 100 g/L, and major comorbidities (renal failure, liver failure, ischemic heart disease, heart failure, disseminated malignancy). Guideline (2002). 55
• A Glasgow Blatchford Score ≤ 1 reliably identifies very low‑risk patients who may be discharged without hospitalization or urgent endoscopy. International Consensus Guideline (2019). 54
• The AIMS65 score should not be used for risk stratification in acute upper GI bleeding. International Consensus Guideline (2019). 54
• Patients exhibiting any high‑risk feature should be admitted to an intensive‑care or monitored unit for at least 24–72 hours. International Consensus Guideline (2019). 54

Pre‑Endoscopic Pharmacologic Management

• Initiate high‑dose intravenous proton‑pump inhibitor (PPI) therapy immediately on presentation, before endoscopy. International Consensus Guideline (2019). 56
• High‑dose IV PPI may downstage endoscopic lesions and reduce the need for endoscopic intervention, but it must not delay endoscopy. International Consensus Guideline (2019). 54
• Routine use of promotility agents (e.g., erythromycin) before endoscopy is not recommended; the guideline explicitly advises against their routine use. International Consensus Guideline (2019). 54
• Endoscopy should not be delayed in patients receiving anticoagulants (warfarin or direct oral anticoagulants). International Consensus Guideline (2019). 54
• Nasogastric tube placement may be considered in selected patients for prognostic information (e.g., bright blood indicating rebleeding), but it is not required routinely. International Consensus Guideline (2019). 54

Timing of Endoscopy

• Perform diagnostic endoscopy within 24 hours of presentation for all hospitalized patients after initial hemodynamic stabilization. International Consensus Guideline (2019). 54

Endoscopic Hemostatic Therapy

• For lesions with high‑risk stigmata (active bleeding or visible vessel), combine epinephrine injection with a second modality—thermal coagulation (bipolar electrocoagulation or heater probe), sclerosant injection, or through‑the‑scope clips. International Consensus Guideline (2019). 54
• Epinephrine injection alone is insufficient and must never be used as sole therapy for hemodynamic control. International Consensus Guideline (2019). 54
• When an adherent clot is encountered, perform targeted irrigation to attempt clot dislodgement, followed by appropriate definitive treatment of the underlying lesion. International Consensus Guideline (2019). 54
• Endoscopic hemostatic therapy is not indicated for low‑risk stigmata such as clean‑based ulcers or flat pigmented spots. Guideline (2002). 55

Post‑Endoscopic Management

• After successful endoscopic therapy for high‑risk stigmata, continue intravenous pantoprazole at 8 mg hour⁻¹ for exactly 72 hours, then switch to oral PPI twice daily for 14 days, followed by once‑daily dosing thereafter (duration adjusted to underlying cause). International Consensus Guideline (2019). 54
• Low‑risk patients may resume oral feeding within 24 hours after endoscopy and can be discharged promptly. International Consensus Guideline (2019). 54

Management of Rebleeding

• If clinical evidence of rebleeding appears (fresh hematemesis, melena, or hemodynamic deterioration), repeat endoscopy is recommended. Guideline (2002). 57

Diagnostic Imaging and Procedural Recommendations in Upper GI Bleed

Imaging for Rebleeding

• In patients with suspected rebleeding after an upper gastrointestinal hemorrhage, contrast‑enhanced CT angiography demonstrates a sensitivity of approximately 79 %–95 % and a specificity of 95 %–100 % for identifying the bleeding source. 58

Nasogastric Tube Use

• Routine placement of a nasogastric tube in acute upper gastrointestinal bleeding does not improve clinical outcomes and is associated with increased complications; therefore it should be avoided as a standard practice. 58

Management of Upper Gastrointestinal Bleeding

Immediate Resuscitation and Hemodynamic Stabilization

• Initiate rapid infusion of 1–2 L isotonic crystalloid (normal saline or Ringer’s lactate) through two large‑bore peripheral IV lines, aiming for heart‑rate reduction, systolic blood‑pressure increase, central venous pressure 5–10 cm H₂O, and urine output > 30 mL/h. 59
• Transfuse packed red blood cells when hemoglobin falls below 80 g/L (8 g/dL) in patients without cardiovascular disease; use a higher threshold (hemoglobin < 100 g/L) for patients with ischemic heart disease, heart failure, or other cardiac comorbidities. 59

Risk Stratification

• Age > 60 years is an independent predictor of mortality; patients > 90 years have a 30 % mortality rate, whereas mortality is rare in patients < 40 years. 59
• Presence of shock (heart rate > 100 bpm and systolic blood pressure < 100 mmHg) identifies high‑risk patients requiring intensive monitoring. 59
• Admission hemoglobin < 100 g/L is associated with increased risk of adverse outcomes. 59
• Major comorbidities—including renal failure, liver failure, ischemic heart disease, heart failure, or disseminated malignancy—significantly raise mortality risk. 59
• A Rockall score > 8 predicts very high mortality (area under ROC curve 0.73–0.81) and is the most validated scale for death prediction after upper GI bleeding. 59
• Low‑risk endoscopic stigmata (clean‑based ulcer or flat pigmented spot) have an excellent prognosis and do not require endoscopic hemostatic therapy. 59

Timing of Endoscopy

• Perform upper endoscopy within 24 hours of presentation for all hospitalized patients after initial hemodynamic stabilization. 59
• For high‑risk patients (persistent hemodynamic instability, shock index > 1, altered mental status, or suspected variceal bleeding), schedule urgent endoscopy within 12 hours. 59

Endoscopic Hemostatic Therapy

• For lesions with high‑risk stigmata (active bleeding or visible vessel), apply combination therapy: epinephrine injection plus a second modality (thermal coagulation, sclerosant injection, or through‑the‑scope clip). 59
• Epinephrine injection alone is insufficient and should never be used as sole therapy because it provides suboptimal efficacy. 59
• Thermal coagulation options include bipolar electrocoagulation or heater probe. 59
• Endoscopic hemostatic therapy is not indicated for low‑risk stigmata (clean‑based ulcers or flat pigmented spots). 59

Post‑Endoscopic Management

• After successful hemostasis of high‑risk lesions, continue intravenous pantoprazole at 8 mg/hour for exactly 72 hours, then switch to oral PPI twice daily for 14 days, followed by once daily thereafter (duration adjusted to the underlying cause). 59
• Admit patients with high‑risk lesions to a monitored setting for at least 72 hours after endoscopic therapy. 59
• Patients classified as low‑risk for rebleeding may resume oral intake within 24 hours and be discharged promptly. 60

Helicobacter pylori Management

• Test all patients presenting with upper GI bleeding for H. pylori infection and provide eradication therapy when positive. [60][59]
• Eradication of H. pylori reduces ulcer recurrence and rebleeding rates in complicated ulcer disease. 60
• Because acute bleeding can yield false‑negative results, perform confirmatory testing after the acute phase if the initial test is negative. 60

Nasogastric Tube Use

• Routine placement of a nasogastric tube is not required; it may be considered only in selected patients for prognostic information, but should be avoided in unsedated patients due to aspiration risk. 61

Evidence‑Based Recommendations for Upper Gastrointestinal Bleeding After Total Abdominal Hysterectomy

Diagnostic Endoscopy – Biopsy

• Obtain a biopsy of any bleeding ulcer to exclude malignancy; this is a strong recommendation (World Journal of Emergency Surgery, 2022) 62

Imaging and Interventional Radiology

• If repeat endoscopy fails, perform CT angiography to localize the bleeding source; reported sensitivity 79–95 % and specificity 95–100 % (World Journal of Emergency Surgery, 2022) 62
• When endoscopic hemostasis is unsuccessful and appropriate expertise/equipment are available, transcatheter angio‑embolization should be considered (World Journal of Emergency Surgery, 2022) 62

Surgical Management

• Do not postpone surgical exploration in unstable patients after failed endoscopic and angiographic therapy (World Journal of Emergency Surgery, 2022) 62
• In hemodynamically unstable patients who do not respond to aggressive resuscitation, immediate diagnostic laparotomy with surgical hemostasis is mandatory (World Journal of Emergency Surgery, 2022) 62

Acute Upper Gastrointestinal Bleeding from Peptic Ulcer Disease: Evidence‑Based Management

Immediate Resuscitation and Stabilization

• Administer 1–2 L of isotonic crystalloid (normal saline or Ringer’s lactate) through two large‑bore peripheral IV lines, targeting systolic blood pressure > 90 mm Hg, heart rate < 100 bpm, central venous pressure 5–10 cm H₂O, and urine output > 30 mL/h. 63
• Prefer crystalloids over colloids because colloids have not shown a survival benefit and are more costly. 63
• Transfuse packed red blood cells when hemoglobin falls below 80 g/L in patients without cardiovascular disease; use a higher threshold (generally > 80–90 g/L) for patients with ischemic heart disease, heart failure, or age > 60 years. 63, 64
• Insert a urinary catheter and monitor hourly urine output, aiming for > 30 mL/h in patients with severe bleeding. 63

Risk Stratification

• Define shock as heart rate > 100 bpm and systolic blood pressure < 100 mm Hg; such patients warrant ICU admission. 63
• Use a Glasgow‑Blatchford score ≤ 1 to identify very low‑risk patients who may be managed as outpatients without hospitalization or urgent endoscopy. 63, 64
• Do not use the AIMS65 score for risk stratification, as it is not recommended. 63, 64

Pre‑Endoscopic Pharmacologic Management

• Initiate pantoprazole 80 mg IV bolus followed by a continuous infusion of 8 mg/h immediately on presentation, before endoscopy. 63
• This high‑dose PPI regimen can downstage endoscopic lesions and reduce the need for intervention, but it must not delay endoscopy. 63, 64
• Avoid routine use of promotility agents (e.g., erythromycin, metoclopramide) before endoscopy, as they do not improve outcomes. 63, 64
• Do not postpone endoscopy in patients receiving warfarin or direct oral anticoagulants; proceed with endoscopy and hemostatic therapy as indicated. 63, 64
• Nasogastric tube placement is not routinely required; consider it only in selected patients for prognostic information (e.g., bright blood indicating higher re‑bleeding risk). 63, 64

Timing of Endoscopy

• Perform endoscopy within 24 hours of presentation for all hospitalized patients after initial hemodynamic stabilization. 63, 64
• For high‑risk patients with persistent hemodynamic instability, altered mental status, or suspected variceal bleeding, conduct urgent endoscopy within 12 hours. 63

Endoscopic Hemostatic Therapy

• For active bleeding (Forrest Ia, Ib) or a visible vessel (Forrest IIa), apply combination therapy: epinephrine injection plus a second modality (thermal coagulation, sclerosant injection, or through‑the‑scope clips). 63
• Epinephrine injection alone is insufficient and must never be used as sole therapy. 63
• Thermal coagulation options include bipolar electrocoagulation or heater probe. 63
• For adherent clot (Forrest IIb), perform vigorous irrigation for at least 5 minutes; if underlying high‑risk stigmata become exposed (occurring in ≈ 30 % of cases), treat with the same combination therapy. 63
• Endoscopic hemostasis is not indicated for clean‑based ulcers (Forrest III) or flat pigmented spots (Forrest IIc). 63

Post‑Endoscopic Management

• After successful hemostasis of high‑risk lesions, continue pantoprazole 8 mg/h IV infusion for a total of 72 hours (including the initial bolus). 63
• After the 72‑hour IV course, switch to oral pantoprazole 40 mg twice daily for 14 days, then once daily thereafter. 63
• Admit patients who received endoscopic therapy for high‑risk lesions to a monitored setting (ICU or step‑down unit) for at least 72 hours, the period of peak re‑bleeding risk. 63
• Low‑risk patients (Forrest IIc, III) may resume oral intake within 24 hours and be discharged promptly if hemodynamically stable. 63

Management of Re‑Bleeding

• If re‑bleeding occurs (e.g., hematemesis, melena, hemodynamic deterioration, falling hemoglobin), perform repeat endoscopy with hemostasis as the first‑line approach. 63

Helicobacter pylori Management

• Test all patients with bleeding peptic ulcers for H. pylori using biopsy during endoscopy and initiate eradication therapy when positive. 63

NSAID Cessation and Secondary Prevention

• Restart aspirin for cardiovascular prophylaxis typically 1–7 days after confirmed hemostasis, when the cardiovascular benefit outweighs bleeding risk. 63
• Aspirin combined with a PPI is superior to clopidogrel alone for preventing re‑bleeding. 63
• All patients with prior ulcer bleeding who require antiplatelet or anticoagulant therapy should receive indefinite PPI co‑therapy. 63

Critical Pitfalls to Avoid

• Do not use epinephrine injection alone for endoscopic hemostasis; it must be combined with thermal or mechanical therapy. 63
• Do not replace aspirin with clopidogrel monotherapy in patients with prior GI bleeding; aspirin plus a PPI provides better protection. 63